Treatment Protocol for Candida auris Invasive Infection
For invasive Candida auris infections, initiate treatment with an echinocandin (micafungin 100 mg daily, caspofungin 70 mg loading then 50 mg daily, or anidulafungin 200 mg loading then 100 mg daily) as first-line therapy, as this class demonstrates superior pharmacodynamic targets and killing activity against C. auris compared to other antifungals. 1, 2
Initial Diagnostic and Treatment Approach
Immediate Actions
- Obtain antifungal susceptibility testing immediately for all C. auris isolates, as this organism exhibits widespread fluconazole resistance (often >90% of isolates) and variable amphotericin B susceptibility 3, 4
- Remove central venous catheters and other indwelling devices within 24-48 hours when feasible, as catheter removal is independently associated with improved survival 5, 6
- Obtain blood cultures every 48-72 hours until clearance is documented 7
First-Line Therapy Selection
Echinocandins are the preferred initial therapy based on:
- C. auris-specific pharmacodynamic data showing micafungin AUC/MIC targets ≥20-fold lower than other Candida species, meaning clinically relevant exposures produce maximal killing 1
- Strong recommendation for echinocandins in invasive candidiasis generally 5
- Clinical outcomes data showing echinocandins associated with survival in pediatric and adult populations 3, 4
Dosing:
- Micafungin: 100 mg IV daily
- Caspofungin: 70 mg IV loading dose, then 50 mg IV daily
- Anidulafungin: 200 mg IV loading dose, then 100 mg IV daily
Alternative and Salvage Therapies
When Echinocandins Cannot Be Used
Liposomal amphotericin B 3-5 mg/kg IV daily is the preferred alternative:
- Use when echinocandin resistance is documented or suspected
- Particularly important for CNS infections (see below)
- Note: C. auris shows variable amphotericin B susceptibility; some isolates are resistant 4, 8
Fluconazole should NOT be used empirically due to widespread resistance, but may be considered only after susceptibility is confirmed 3, 4
Site-Specific Modifications
CNS Infections (Meningitis/Ventriculitis):
- Liposomal amphotericin B 5 mg/kg IV daily PLUS flucytosine 25 mg/kg PO/IV four times daily 5, 9
- Echinocandins have limited CNS penetration and should be avoided for primary CNS disease 5
- Remove infected ventriculostomy drains and shunts if present 5, 9
- Continue until all CSF abnormalities and symptoms resolve 5
Urinary Tract Infections:
- For symptomatic UTI: Echinocandin or liposomal amphotericin B 3-5 mg/kg daily 10
- Fluconazole 400 mg daily only if susceptibility confirmed 10
- Consider amphotericin B bladder irrigation for persistent infection 10
- Aggressive treatment recommended to prevent invasive spread 10
Endocarditis:
- Liposomal amphotericin B 3-5 mg/kg daily with or without flucytosine OR high-dose echinocandin (caspofungin 150 mg, micafungin 150 mg, or anidulafungin 200 mg daily) 5
- Valve replacement strongly recommended 5
- Continue therapy ≥6 weeks post-surgery 5
Combination Therapy Considerations
Combination therapy may be considered for:
- Pan-resistant isolates (resistant to both echinocandins and amphotericin B) 4
- Persistent candidemia despite appropriate monotherapy
- CNS infections (amphotericin B + flucytosine) 5, 9
Numerically higher survival observed with combination therapy in some pediatric series, though data remain limited 3
Duration of Therapy
Standard candidemia without metastatic complications:
- Continue for 14 days after documented clearance from bloodstream AND resolution of attributable symptoms 5
- Repeat blood cultures every 48-72 hours until negative 7
Deep-seated infections:
- Continue until complete resolution on repeat imaging (often several months) 5
- Premature discontinuation leads to relapse 5
Step-Down Therapy
Consider oral step-down only after:
- Clinical stability achieved
- Blood cultures cleared
- Susceptibility results available
- Minimum 5 days of IV therapy completed 6
Options (only if susceptible):
- Fluconazole 400-800 mg daily (if susceptible) 5
- Voriconazole 200-300 mg twice daily (if susceptible but fluconazole-resistant) 5
Critical caveat: Most C. auris isolates are fluconazole-resistant, making step-down therapy often not feasible 3, 4
Monitoring and Follow-Up
Essential Monitoring
- Blood cultures every 48-72 hours until clearance 7
- Dilated funduscopic examination within first week to evaluate for endophthalmitis 7
- For neutropenic patients, defer eye exam until neutrophil recovery 5
- Imaging (CT/ultrasound) of liver, spleen, kidneys if persistent positive cultures 5
Predictors of Clinical Cure
Based on multivariable analysis, clinical cure depends on:
- Mycologic cure (OR 6.96) - most important predictor
- Shorter ICU length of stay
- Lower baseline C-reactive protein levels 4
Infection Control Measures
Implement strict contact precautions:
- Single room isolation
- Dedicated equipment
- Enhanced environmental cleaning with sporicidal agents
- Screen contacts for colonization
- C. auris persists on surfaces and spreads readily in healthcare settings 2, 11
Common Pitfalls to Avoid
- Do not use fluconazole empirically - resistance rates exceed 90% in most C. auris isolates 3, 4
- Do not use echinocandins for CNS infections - inadequate penetration 5
- Do not delay catheter removal - independently associated with mortality 6
- Do not stop therapy prematurely - leads to relapse and recurrence (28.6% at 30 days in one series) 4
- Do not rely on standard biochemical identification - C. auris is commonly misidentified; requires MALDI-TOF or molecular methods 12, 8
Expected Outcomes
- 30-day all-cause mortality: 28.6-35% 3, 4
- Mycologic cure: 84.4% with appropriate therapy 4
- 30-day recurrence: 28.6% 4
- Clinical cure: 57% 4
These mortality rates are similar to other invasive Candida species despite multidrug resistance, emphasizing the importance of early appropriate therapy with echinocandins 3